Ischemic StrokeNCT07834333
Effectiveness of Theta Burst Stimulation For Upper and Lower Extremity Recovery in Stroke
A study testing Continuous Theta Burst Stimulation (cTBS) and Intermittent Theta Burst Stimulation (iTBS) in people with Ischemic Stroke, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).
Trial summary
This single-center, single-blind, randomized, sham-controlled clinical trial will include 60 patients aged >45 years who are within 3 months of a first-ever middle cerebral artery ischemic stroke. Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Ischemic Stroke
- What is being tested?
- Continuous Theta Burst Stimulation (cTBS) and Intermittent Theta Burst Stimulation (iTBS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 30 Sep 2026to 30 Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of ischemic stroke due to middle cerebral artery (MCA) occlusion confirmed by magnetic resonance imaging (MRI).
- Within the first 3 months after stroke.
- First-ever stroke.
- Age ≥45 years.
- Brunnstrom stage 1, 2, or 3 for the upper extremity and hand.
- No previous physical therapy after the current stroke.
Show all 10Show fewer
- Ability to maintain at least minimal semi-sitting balance.
- Medically and neurologically stable.
- Mini-Mental State Examination score >24.
- Native Turkish speaker who voluntarily agrees to participate and provides written informed consent.
Who cannot join
- History of epilepsy.
- Presence of a pacemaker.
- Pregnancy.
- Neurological disease other than stroke.
- Metallic implants in the brain or scalp, including cochlear implants.
- History of brain surgery.
Show all 14Show fewer
- Comorbid disease that may significantly impair general health, such as heart f-failure or chronic obstructive pulmonary disease, and/or severe infection.
- Diagnosis of malignancy.
- Peripheral nerve injury and/or musculoskeletal disorder affecting motor function of the upper or lower extremities, such as fracture.
- Cardiac arrhythmia.
- Aphasia, spatial neglect, or visual field loss.
- Visual or hearing impairment that prevents communication.
- Alcohol and/or drug dependence.
- Refusal to participate or failure to provide informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Ankara Etlik Şehir Hastanesi
Ankara, Yenimahalle, 06170
Fatma Melis Ertuğrul Öztürk, Resident, 03127970000, melis.ertugrul@hotmail.com
About this study
Official title: Effects of Different Theta Burst Stimulation Protocols Combined With Conventional Rehabilitation on Upper and Lower Extremity Motor Recovery in Patients With Early-Stage Stroke
This single-center, single-blind, randomized, sham-controlled clinical trial will include 60 patients aged >45 years who are within 3 months of a first-ever middle cerebral artery ischemic stroke. Participants will be randomized into four groups: coupled TBS (contralesional cTBS followed by ipsilesional iTBS), cTBS plus sham iTBS, sham cTBS plus iTBS, or sham TBS. TBS will be delivered over the primary motor cortex for 10 sessions over 2 weeks. Stimulation intensity will be set at 80% of the resting motor threshold determined using EMG-guided motor evoked potentials. Each cTBS and iTBS application will consist of 600 pulses. All participants will additionally receive standardized conventional rehabilitation for at least 4 weeks.
The primary outcome will be upper-extremity motor recovery assessed using the motor domain of the Fugl-Meyer Assessment. Secondary outcomes will include lower-extremity motor recovery, spasticity, sensory function, cortical excitability, functional ambulation, activities of daily living, and stroke-specific quality of life. Assessments will be performed at baseline, after the 2-week intervention, and at 1-month post-treatment follow-up.
- Conditions
- Ischemic Stroke
- Being tested
- Continuous Theta Burst Stimulation (cTBS), Intermittent Theta Burst Stimulation (iTBS), Sham Continuous Theta Burst Stimulation, Sham Intermittent Theta Burst Stimulation
- Keywords
- Theta Burst Stimulation, Stroke Rehabilitation, Motor Recovery, Upper Extremity Motor Function, Lower Extremity Motor Function, Cortical Excitability, Transcranial Magnetic Stimulation
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous Theta Burst Stimulation (cTBS)Device
Continuous theta burst stimulation will be applied over the contralesional primary motor cortex (M1) at 80% of the resting motor threshold. A total of 600 pulses will be delivered over 40 seconds as triplets at 50 Hz repeated every 200 ms.
Intermittent Theta Burst Stimulation (iTBS)Device
Intermittent theta burst stimulation will be applied over the ipsilesional primary motor cortex (M1) at 80% of the resting motor threshold. A total of 600 pulses will be delivered over approximately 190 seconds using 2-second trains repeated every 10 seconds.
Sham Continuous Theta Burst StimulationDevice
Sham continuous theta burst stimulation will be delivered over the contralesional primary motor cortex using a sham coil for 40 seconds.
Sham Intermittent Theta Burst StimulationDevice
Sham intermittent theta burst stimulation will be delivered over the ipsilesional primary motor cortex using a sham coil for approximately 190 seconds.
| Study group | Role | What they receive |
|---|---|---|
| Coupled TBS Group | Experimental | Participants will receive contralesional continuous theta burst stimulation (cTBS) followed by ipsilesional intermittent theta burst stimulation (iTBS) within the same session. Ten sessions will be administered over 2 weeks in addition to standardized conventional rehabilitation. Receives: Device: Continuous Theta Burst Stimulation (cTBS); Device: Intermittent Theta Burst Stimulation (iTBS) |
| cTBS + Sham iTBS Group | Experimental | Participants will receive contralesional continuous theta burst stimulation (cTBS) followed by ipsilesional sham intermittent theta burst stimulation (sham iTBS) within the same session. Ten sessions will be administered over 2 weeks in addition to standardized conventional rehabilitation. Receives: Device: Continuous Theta Burst Stimulation (cTBS); Device: Sham Intermittent Theta Burst Stimulation |
| Sham cTBS + iTBS Group | Experimental | Participants will receive contralesional sham continuous theta burst stimulation (sham cTBS) followed by ipsilesional intermittent theta burst stimulation (iTBS) within the same session. Ten sessions will be administered over 2 weeks in addition to standardized conventional rehabilitation. Receives: Device: Intermittent Theta Burst Stimulation (iTBS); Device: Sham Continuous Theta Burst Stimulation |
| Sham TBS Group | Sham comparator | Participants will receive contralesional sham continuous theta burst stimulation (sham cTBS) followed by ipsilesional sham intermittent theta burst stimulation (sham iTBS) within the same session. Ten sessions will be administered over 2 weeks in addition to standardized conventional rehabilitation. Receives: Device: Sham Continuous Theta Burst Stimulation; Device: Sham Intermittent Theta Burst Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Upper Extremity Motor Function Assessed by the Fugl-Meyer Assessment - Upper Extremity Motor Subscale (FMA-UE)
Upper extremity motor function will be assessed using the motor subsection of the Fugl-Meyer Assessment. The FMA-UE motor score ranges from 0 to 66, with higher scores indicating better upper extremity motor function. Each item is scored on a 3-point ordinal scale: 0 = cannot perform, 1 = performs partially, and 2 = performs fully
Measured: Baseline, Week 2, and Week 6
Change in Lower Extremity Motor Function Assessed by the Fugl-Meyer Assessment - Lower Extremity Motor Subscale
Lower extremity motor recovery will be assessed using the lower extremity motor subsection of the Fugl-Meyer Assessment.
Measured: Baseline, Week 2, and Week 6
Change in Motor Recovery Stage Assessed by the Brunnstrom Motor Recovery Stages
Motor recovery of the upper and lower extremities will be evaluated using the Brunnstrom Motor Recovery Stages. Each assessed region is rated separately from stage I (1) to stage VI (6), with higher stages indicating better motor recovery.
Measured: Baseline, Week 2, and Week 6
Secondary outcomes (7)
Change in Spasticity Assessed by the Modified Ashworth Scale
Spasticity of the upper and lower extremities will be assessed using the Modified Ashworth Scale (MAS). Scores range from 0 (no increase in muscle tone) to 4 (rigidity in flexion or extension), with six ordinal categories: 0, 1, 1+, 2, 3, and 4. Higher scores indicate greater muscle tone and resistance to passive movement, representing a worse outcome.
Measured: Baseline, Week 2, and Week 6
Change in Sensory Function Assessed by the Fugl-Meyer Assessment - Sensory Subscale
Sensory function of the upper and lower extremities will be assessed using the sensory subsection of the Fugl-Meyer Assessment. This subsection evaluates light touch and joint position sense, with each item scored on a three-point ordinal scale (0-2). The combined sensory score for the upper and lower extremities ranges from 0 to 24, with higher scores indicating better sensory function.
Measured: Baseline, Week 2, and Week 6
Change in Cortical Excitability Assessed by Motor Evoked Potential Amplitude
Cortical excitability will be evaluated by measuring motor evoked potential (MEP) amplitude.
Measured: Baseline, Week 2, and Week 6
Change in Cortical Excitability Assessed by Motor Evoked Potential Latency
Cortical excitability will be evaluated by measuring motor evoked potential (MEP) latency.
Measured: Baseline, Week 2, and Week 6
Change in Functional Ambulation Assessed by the Functional Ambulation Scale
Functional ambulation will be assessed using the Functional Ambulation Scale (FAS). The scale consists of six ordinal categories ranging from 0 to 5. A score of 0 indicates an inability to walk or the need for assistance from two or more people, whereas a score of 5 indicates independent walking on level and uneven surfaces, including stairs. Higher scores indicate greater independence in walking and a better functional outcome.
Measured: Baseline, Week 2, and Week 6
Change in Independence in Activities of Daily Living Assessed by the Modified Barthel Index
Independence in activities of daily living and mobility will be assessed using the Modified Barthel Index. The index consists of 10 items, with item scores summed to yield a total score ranging from 0 to 100. A score of 0 indicates total dependence, whereas a score of 100 indicates independence in all assessed activities. Higher scores indicate greater functional independence and a better outcome.
Measured: Baseline, Week 2, and Week 6
Change in Stroke-Specific Quality of Life
Stroke-specific quality of life will be assessed using the Turkish version of the Stroke-Specific Quality of Life Scale (SS-QOL). The scale consists of 48 items across eight domains. Each item is rated on a five-point scale ranging from 1 to 5. The mean item score will be calculated by averaging the scores of all 48 items, resulting in an overall score ranging from 1 to 5, with higher scores indicating better health-related quality of life.
Measured: Baseline, Week 2, and Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2026
- Study start30 Sep 2026
- Primary completion30 Aug 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by Ankara Etlik City HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ankara Etlik City Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Ayse Naz Kalem, Ankara Etlik City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07834333
- Sponsor's protocol ID
- AEŞH-2025-070
- Status last verified
- Nov 2026
- First submitted
- 28 Aug 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Long H, Wang H, Zhao C, Duan Q, Feng F, Hui N, Mao L, Liu H, Mou X, Yuan H. Effects of combining high- and low-frequency repetitive transcranial magnetic stimulation on upper limb hemiparesis in the early phase of stroke. Restor Neurol Neurosci. 2018;36(1):21-30. doi: 10.3233/RNN-170733.
PubMed 29439359Kuzu O, Adiguzel E, Kesikburun S, Yasar E, Yilmaz B. The Effect of Sham Controlled Continuous Theta Burst Stimulation and Low Frequency Repetitive Transcranial Magnetic Stimulation on Upper Extremity Spasticity and Functional Recovery in Chronic Ischemic Stroke Patients. J Stroke Cerebrovasc Dis. 2021 Jul;30(7):105795. doi: 10.1016/j.jstrokecerebrovasdis.2021.105795. Epub 2021 Apr 20.
PubMed 33887662Chen Q, Shen D, Sun H, Ke J, Wang H, Pan S, Liu H, Wang D, Su M, Fang Q. Effects of coupling inhibitory and facilitatory repetitive transcranial magnetic stimulation on motor recovery in patients following acute cerebral infarction. NeuroRehabilitation. 2021;48(1):83-96. doi: 10.3233/NRE-201606.
PubMed 33361618Fu Y, Wang C, Zhang L, Ji D, Xiang A, Qi J, Zhao R, Wu L, Jin S, Zhang Q. The effectiveness of theta burst stimulation for motor recovery after stroke: a systematic review. Eur J Med Res. 2024 Nov 29;29(1):568. doi: 10.1186/s40001-024-02170-2.
PubMed 39609900Meng Y, Zhang D, Hai H, Zhao YY, Ma YW. Efficacy of coupling intermittent theta-burst stimulation and 1 Hz repetitive transcranial magnetic stimulation to enhance upper limb motor recovery in subacute stroke patients: A randomized controlled trial. Restor Neurol Neurosci. 2020;38(1):109-118. doi: 10.3233/RNN-190953.
PubMed 32039879
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Different Theta Burst Stimulation Protocols Combined With Conventional Rehabilitation on Upper and Lower Extremity Motor Recovery in Patients With Early-Stage Stroke
- ClinicalTrials.gov ID
- NCT07834333
- Acronym / sponsor ID
- AEŞH-2025-070
- Conditions
- Ischemic Stroke
- Keywords
- Theta Burst Stimulation, Stroke Rehabilitation, Motor Recovery, Upper Extremity Motor Function, Lower Extremity Motor Function, Cortical Excitability, Transcranial Magnetic Stimulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Ankara Etlik City HospitalOther government
- Study start
- 30 Sep 2026 (actual)
- Primary completion
- 30 Aug 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 22 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single-center, single-blind, randomized, sham-controlled clinical trial will include 60 patients aged >45 years who are within 3 months of a first-ever middle cerebral artery ischemic stroke. Participants will be randomized into four groups: coupled TBS (contralesional cTBS followed by ipsilesional iTBS), cTBS plus sham iTBS, sham cTBS plus iTBS, or sham TBS. TBS will be delivered over the primary motor cortex for 10 sessions over 2 weeks. Stimulation intensity will be set at 80% of the resting motor threshold determined using EMG-guided motor evoked potentials. Each cTBS and iTBS application will consist of 600 pulses. All participants will additionally receive standardized conventional rehabilitation for at least 4 weeks.
The primary outcome will be upper-extremity motor recovery assessed using the motor domain of the Fugl-Meyer Assessment. Secondary outcomes will include lower-extremity motor recovery, spasticity, sensory function, cortical excitability, functional ambulation, activities of daily living, and stroke-specific quality of life. Assessments will be performed at baseline, after the 2-week intervention, and at 1-month post-treatment follow-up.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Coupled TBS Group | Experimental | Device: Continuous Theta Burst Stimulation (cTBS), Device: Intermittent Theta Burst Stimulation (iTBS)Participants will receive contralesional continuous theta burst stimulation (cTBS) followed by ipsilesional intermittent theta burst stimulation (iTBS) within the same session. Ten sessions will be administered over 2 weeks in addition to standardized conventional rehabilitation. |
| cTBS + Sham iTBS Group | Experimental | Device: Continuous Theta Burst Stimulation (cTBS), Device: Sham Intermittent Theta Burst StimulationParticipants will receive contralesional continuous theta burst stimulation (cTBS) followed by ipsilesional sham intermittent theta burst stimulation (sham iTBS) within the same session. Ten sessions will be administered over 2 weeks in addition to standardized conventional rehabilitation. |
| Sham cTBS + iTBS Group | Experimental | Device: Intermittent Theta Burst Stimulation (iTBS), Device: Sham Continuous Theta Burst StimulationParticipants will receive contralesional sham continuous theta burst stimulation (sham cTBS) followed by ipsilesional intermittent theta burst stimulation (iTBS) within the same session. Ten sessions will be administered over 2 weeks in addition to standardized conventional rehabilitation. |
| Sham TBS Group | Sham comparator | Device: Sham Continuous Theta Burst Stimulation, Device: Sham Intermittent Theta Burst StimulationParticipants will receive contralesional sham continuous theta burst stimulation (sham cTBS) followed by ipsilesional sham intermittent theta burst stimulation (sham iTBS) within the same session. Ten sessions will be administered over 2 weeks in addition to standardized conventional rehabilitation. |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Diagnosis of ischemic stroke due to middle cerebral artery (MCA) occlusion confirmed by magnetic resonance imaging (MRI).
- Within the first 3 months after stroke.
- First-ever stroke.
- Age ≥45 years.
- Brunnstrom stage 1, 2, or 3 for the upper extremity and hand.
Key exclusion criteria (14 listed)
- History of epilepsy.
- Presence of a pacemaker.
- Pregnancy.
- Neurological disease other than stroke.
- Metallic implants in the brain or scalp, including cochlear implants.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous Theta Burst Stimulation (cTBS)Continuous theta burst stimulation will be applied over the contralesional primary motor cortex (M1) at 80% of the resting motor threshold. A total of 600 pulses will be delivered over 40 seconds as triplets at 50 Hz repeated every 200 ms. | Device | Coupled TBS Group, cTBS + Sham iTBS Group |
| Intermittent Theta Burst Stimulation (iTBS)Intermittent theta burst stimulation will be applied over the ipsilesional primary motor cortex (M1) at 80% of the resting motor threshold. A total of 600 pulses will be delivered over approximately 190 seconds using 2-second trains repeated every 10 seconds. | Device | Coupled TBS Group, Sham cTBS + iTBS Group |
| Sham Continuous Theta Burst StimulationSham continuous theta burst stimulation will be delivered over the contralesional primary motor cortex using a sham coil for 40 seconds. | Device | Sham TBS Group, Sham cTBS + iTBS Group |
| Sham Intermittent Theta Burst StimulationSham intermittent theta burst stimulation will be delivered over the ipsilesional primary motor cortex using a sham coil for approximately 190 seconds. | Device | Sham TBS Group, cTBS + Sham iTBS Group |
Primary outcome
Change in Upper Extremity Motor Function Assessed by the Fugl-Meyer Assessment - Upper Extremity Motor Subscale (FMA-UE)
Time frame: Baseline, Week 2, and Week 6
Upper extremity motor function will be assessed using the motor subsection of the Fugl-Meyer Assessment. The FMA-UE motor score ranges from 0 to 66, with higher scores indicating better upper extremity motor function. Each item is scored on a 3-point ordinal scale: 0 = cannot perform, 1 = performs partially, and 2 = performs fully
Change in Lower Extremity Motor Function Assessed by the Fugl-Meyer Assessment - Lower Extremity Motor Subscale
Time frame: Baseline, Week 2, and Week 6
Lower extremity motor recovery will be assessed using the lower extremity motor subsection of the Fugl-Meyer Assessment.
Change in Motor Recovery Stage Assessed by the Brunnstrom Motor Recovery Stages
Time frame: Baseline, Week 2, and Week 6
Motor recovery of the upper and lower extremities will be evaluated using the Brunnstrom Motor Recovery Stages. Each assessed region is rated separately from stage I (1) to stage VI (6), with higher stages indicating better motor recovery.
7 secondary outcomes
Change in Spasticity Assessed by the Modified Ashworth Scale
Time frame: Baseline, Week 2, and Week 6
Change in Sensory Function Assessed by the Fugl-Meyer Assessment - Sensory Subscale
Time frame: Baseline, Week 2, and Week 6
Change in Cortical Excitability Assessed by Motor Evoked Potential Amplitude
Time frame: Baseline, Week 2, and Week 6
Change in Cortical Excitability Assessed by Motor Evoked Potential Latency
Time frame: Baseline, Week 2, and Week 6
Change in Functional Ambulation Assessed by the Functional Ambulation Scale
Time frame: Baseline, Week 2, and Week 6
Change in Independence in Activities of Daily Living Assessed by the Modified Barthel Index
Time frame: Baseline, Week 2, and Week 6
Change in Stroke-Specific Quality of Life
Time frame: Baseline, Week 2, and Week 6
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Background: PubMed 29439359Long H, Wang H, Zhao C, Duan Q, Feng F, Hui N, Mao L, Liu H, Mou X, Yuan H. Effects of combining high- and low-frequency repetitive transcranial magnetic stimulation on upper limb hemiparesis in the early phase of stroke. Restor Neurol Neurosci. 2018;36(1):21-30. doi: 10.3233/RNN-170733.
- Background: PubMed 33887662Kuzu O, Adiguzel E, Kesikburun S, Yasar E, Yilmaz B. The Effect of Sham Controlled Continuous Theta Burst Stimulation and Low Frequency Repetitive Transcranial Magnetic Stimulation on Upper Extremity Spasticity and Functional Recovery in Chronic Ischemic Stroke Patients. J Stroke Cerebrovasc Dis. 2021 Jul;30(7):105795. doi: 10.1016/j.jstrokecerebrovasdis.2021.105795. Epub 2021 Apr 20.
- Background: PubMed 33361618Chen Q, Shen D, Sun H, Ke J, Wang H, Pan S, Liu H, Wang D, Su M, Fang Q. Effects of coupling inhibitory and facilitatory repetitive transcranial magnetic stimulation on motor recovery in patients following acute cerebral infarction. NeuroRehabilitation. 2021;48(1):83-96. doi: 10.3233/NRE-201606.
- Background: PubMed 39609900Fu Y, Wang C, Zhang L, Ji D, Xiang A, Qi J, Zhao R, Wu L, Jin S, Zhang Q. The effectiveness of theta burst stimulation for motor recovery after stroke: a systematic review. Eur J Med Res. 2024 Nov 29;29(1):568. doi: 10.1186/s40001-024-02170-2.
- Background: PubMed 32039879Meng Y, Zhang D, Hai H, Zhao YY, Ma YW. Efficacy of coupling intermittent theta-burst stimulation and 1 Hz repetitive transcranial magnetic stimulation to enhance upper limb motor recovery in subacute stroke patients: A randomized controlled trial. Restor Neurol Neurosci. 2020;38(1):109-118. doi: 10.3233/RNN-190953.
- Individual participant dataSharing planned: No
Related trials for Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous Theta Burst Stimulation (cTBS) and Intermittent Theta Burst Stimulation (iTBS) in people with Ischemic Stroke, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fatma Melis Ertuğrul Öztürk, Resident (03127970000, melis.ertugrul@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Upper Extremity Motor Function Assessed by the Fugl-Meyer Assessment - Upper Extremity Motor Subscale (FMA-UE) (time frame: Baseline, Week 2, and Week 6). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07834333, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.